BIXT BIOXYTRAN INC

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases

- Leading drug candidate ProLectin-M targets galectins in viral infections including bird flu like viruses

BOSTON, MASSACHUSETTS, April 11, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel therapies targeting hypoxia and mitochondrial dysfunction, today highlighted the historical and scientific significance of fiber optic–based fluorometry in brain mitochondrial research. A landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University was published in a book compiled by editor George Laliotis which covered key areas of biological science. Bioxytran believes this is a milestone achievement because the study, commemorates 50 years of in vivo NADH redox state monitoring, highlighting the pivotal role of mitochondrial function in cellular health. This is a cornerstone of Bioxytran’s BXT-25 drug development program.

The recent paper emphasizes the significance of real-time mitochondrial monitoring, particularly in addressing mitochondrial dysfunction and hypoxia—key contributors to diseases like stroke.

The groundbreaking work of Prof. Mayevsky, which introduced UV-transmitting optical fibers for tracking NADH fluorescence in vivo, paved the way for development of the MDX Viewer with is an FDA approved device that measures tissue metabolic score in real time.

Bioxytran is advancing BXT-25 toward Phase 1 trials for conditions where an oxygen transport carrier is needed to burrow through blood clots including ischemic stroke, heart attack, pulmonary embolism, chronic kidney disease (CKD), and Long Covid. The company is also exploring partnerships to integrate next-generation monitoring technologies for patient selection and use as a new vital sign.

“This anniversary paper mirrors our mission at Bioxytran —to translate decades of foundational science into life-saving therapies,” stated David Platt, CEO of Bioxytran Inc. “BXT-25 builds on these principles by directly addressing the mitochondrial dysfunction observed in hypoxia-related diseases. Prof. Mayevsky’s work validates the urgency of our clinical efforts."

About Bioxytran, Inc.

Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. For more information, visit

Investor Relations

Michael Sheikh

509-991-0245

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.



EN
11/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOXYTRAN INC

 PRESS RELEASE

Bioxytran Secures a Source of GMP Quality Camel Hemoglobin

Bioxytran Secures a Source of GMP Quality Camel Hemoglobin - First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke, Alzheimer’s disease, and viruses, has a secured a GMP quality source of camel hemoglobin with help from the Heme Foundation. The Heme foundation, dedicated to solving the worlds blood shortages, is partnered with Bioxytran i...

 PRESS RELEASE

Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation ...

Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiolog...

 PRESS RELEASE

Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s...

Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission PHM23 was one of a handful of molecules chosen by the universityBird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing breakthrough antiviral treatments, announced that the University of Georgia confirmed the antiviral PHM23 was to be included amongst other drug candidates in the ...

 PRESS RELEASE

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its antiviral drug ProLectin-M in a randomized double-blind placebo-controlled trial. Preliminary results are expected, with full data submission to the FDA under Bioxytran’s active Investigational New Drug (IND) clinical trials for ProLectin-M. Key Trial Details: - Evaluated mul...

 PRESS RELEASE

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advance...

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases - Leading drug candidate ProLectin-M targets galectins in viral infections including bird flu like viruses BOSTON, MASSACHUSETTS, April 11, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel therapies targeting hypoxia and mitochondrial dysfunction, today highlighted the historical and scientific signifi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch